These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2278639)

  • 21. Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.
    Maekawa T; Osawa Y; Izumi T; Nagao S; Takano K; Okada Y; Tachi N; Teramoto M; Kawamura T; Horiuchi T; Saga R; Kato S; Yamamura T; Watanabe J; Kobayashi A; Kobayashi S; Sato K; Hashimoto M; Suzu S; Kimura F
    Leukemia; 2017 Dec; 31(12):2709-2716. PubMed ID: 28386106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic options for patients with myelofibrosis in blast phase.
    Mascarenhas J; Navada S; Malone A; Rodriguez A; Najfeld V; Hoffman R
    Leuk Res; 2010 Sep; 34(9):1246-9. PubMed ID: 20627294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM
    Ann Hematol; 2006 Apr; 85(4):226-32. PubMed ID: 16421727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management.
    Garmezy B; Schaefer JK; Mercer J; Talpaz M
    Blood Rev; 2021 Jan; 45():100691. PubMed ID: 32354563
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Idiopathic myelofibrosis: historical review, diagnosis and management.
    Weinstein IM
    Blood Rev; 1991 Jun; 5(2):98-104. PubMed ID: 1912760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myelosuppression toxicity of palliative splenic irradiation in myelofibrosis and malignant lymphoma.
    Ishibashi N; Maebayashi T; Aizawa T; Sakaguchi M; Abe O; Saito T; Tanaka Y
    Hematology; 2015 May; 20(4):203-7. PubMed ID: 25131182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pattern and clinical significance of karyotypic abnormalities in patients with idiopathic and postpolycythemic myelofibrosis.
    Miller JB; Testa JR; Lindgren V; Rowley JD
    Cancer; 1985 Feb; 55(3):582-91. PubMed ID: 3965109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current perspective in agnogenic myeloid metaplasia.
    Tefferi A; Silverstein MN
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():169-71. PubMed ID: 8951788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiopathic myelofibrosis: pathogenesis to treatment.
    Reilly JT
    Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current views on the pathogenesis and treatment of spontaneous (primary) myelofibrosis].
    Robak T
    Pol Tyg Lek; 1992 Feb 3-10; 47(5-6):144-7. PubMed ID: 1437804
    [No Abstract]   [Full Text] [Related]  

  • 32. Acute myelofibrosis--a leukemia of pluripotent stem cell. A report of three cases and review of the literature.
    Amberger DM; Saleem A; Kemp BL; Truong LD
    Ann Clin Lab Sci; 1990; 20(6):409-14. PubMed ID: 2073090
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inability of immunomorphometric assessment of angiogenesis to distinguish primary versus secondary myelofibrosis.
    Sharma P; Pati HP; Mishra PC; Dinda AK; Gupta R; Sharma A; Jacob TG
    Anal Quant Cytol Histol; 2011 Aug; 33(4):236-44. PubMed ID: 21980629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
    Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
    Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Splenectomy in idiopathic thrombopenic purpura and in myelofibrosis. A retrospective study of platelet increase, hemorrhagic complications and mortality].
    Hellström P; Ogier C; Askergren J; Sundblad R; Reizenstein P
    Minerva Chir; 1981 Sep; 36(17):1065-8. PubMed ID: 7197336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasonic characterization of splenic tissue in myelofibrosis: further evidence for reversal of fibrosis with chemotherapy.
    Manoharan A; Chen CF; Wilson LS; Griffiths KA; Robinson DE
    Eur J Haematol; 1988 Feb; 40(2):149-54. PubMed ID: 3278929
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treating early-stage myelofibrosis.
    Palandri F; Sabattini E; Maffioli M
    Ann Hematol; 2019 Feb; 98(2):241-253. PubMed ID: 30343328
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone marrow angiogenesis and its clinical correlates in myelofibrosis with myeloid metaplasia.
    Arora B; Ho CL; Hoyer JD; Mesa RA; Tefferi A
    Haematologica; 2004 Dec; 89(12):1454-8. PubMed ID: 15590395
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia.
    Buesche G; Ganser A; Schlegelberger B; von Neuhoff N; Gadzicki D; Hecker H; Bock O; Frye B; Kreipe H
    Leukemia; 2007 Dec; 21(12):2420-7. PubMed ID: 17805334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A sequential histological study of bone marrow fibrosis in idiopathic myelofibrosis.
    Hasselbalch H; Lisse I
    Eur J Haematol; 1991 May; 46(5):285-9. PubMed ID: 2044723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.